Rusfertide
Approved in the US in August 2026 for polycythemia vera.
A copy of , the hormone that rations iron. By limiting the iron available to make red blood cells, it reduces the need for blood removal (phlebotomy) in . Made by Takeda (with Protagonist), also called Mimrylo and PTG-300.
What the evidence shows
Side effects and risks
Who should avoid it: Use for anything other than its approved blood condition.
How it works
- Where it acts
- It copies hepcidin and binds ferroportin, the channel iron uses to leave cells.
- What it changes
- Less iron reaches the bone marrow, so fewer red blood cells are made.
- What people notice
- Fewer blood removals (phlebotomies) needed. Injection-site reactions are common.
How it is taken
A weekly self-injection under the skin, alongside usual treatment.
Getting it in the United States
The legal route for Rusfertide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Specialist prescription
List price is 4,200 dollars a vial, about 218,000 dollars a year. Available at once after approval. The label does not require trying other drugs first.
Source: Pharmaphorum, 2026-08
Maker assistance programmes
Commercially insured patients may get a zero copay. The maker offers up to two months free while insurance is sorted and a programme for uninsured patients. Payer talks were ongoing at launch.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextCase reports, what public figures say, videos and articles and when options run out
Case reports
From journals, regulators and studies of users. One case proves little.
Benefit reportedtrial result in rare group - 293 people - 2026
In the VERIFY trial, about 77 percent on rusfertide needed no blood removal over the test period versus 33 percent on placebo. Injection site reactions hit nearly half. Anemia affected about a quarter.
Source: OncLive, 2026-08
What experts and influencers say
Paraphrased from the linked sources.
Said it seems very well tolerated but patients will be the judge. Expects most patients to use it at some point, maybe not for life, and often with other drugs.
Source: Cancer Network, 2026-08
Andrew KuykendallWebsiteRecommends
Money: Lead investigator of the company-sponsored trial
Photo source: moffitt.org
Said people with polycythemia vera have long faced frequent blood removal and the approval could cut that burden.
Source: Targeted Oncology, 2026-08
Tanya WroblewskiSourceRecommends
Called the approval important progress and said patients have long needed more treatment choices.
Source: Targeted Oncology, 2026-08
Kapila VigesWebsiteRecommends
Photo source: milkeninstitute.org
Said the label is broader than expected because no prior drug is required. Projects peak sales near 2 billion dollars a year.
Source: BioPharma Dive, 2026-08
Stephen BarkerWebsiteRecommends
Money: Covers Takeda with a buy rating
Photo source: votefor.jefferies.com
A spokesperson defended the list price as matching the drug's value and said the company is working with insurers so cost does not block suitable patients.
Money: Sells the drug
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Protagonist drug hits goals in pivotal study of rare blood cancer
Adam Feuerstein, STAT senior biotech writer
Reports that rusfertide met its main goals in the phase 3 polycythemia vera trial, with filings planned. Part of it sits behind the STAT+ paywall.
First report of the pivotal trial result.
ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap
Darren Incorvaia, reporter
Conference report: longer rusfertide phase 3 data showed nearly 78 percent of patients avoiding blood draws late on, versus a rival drug's early data.
Puts rusfertide's results next to a competing approach.
FDA approves Protagonist and Takeda's drug for rare blood cancer
Adam Feuerstein, STAT senior biotech writer
Reports FDA approval of Mimrylo, a once-weekly rusfertide shot for polycythemia vera, and why excess red blood cells raise clot risk. Partly paywalled.
The approval news, with plain disease context.
When options run out
Uses people turn to when standard treatment has failed.
Blood counts uncontrolled on standard care
- Who
- Polycythemia vera patients still needing frequent blood removal despite hydroxyurea or other drugs.
- Evidence
- One 293-person phase 3 trial as add-on therapy. Long-term safety follow-up continues to 156 weeks.
- Route
- Approved use
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
What does rusfertide do?
It copies hepcidin, the hormone that rations iron. By limiting the iron available to make red blood cells, it reduces the need for blood removal (phlebotomy) in polycythemia vera.
How well does rusfertide work?
In the VERIFY trial, 77% of people needed no phlebotomy between weeks 20 and 32, against 33% on placebo.
What are the side effects of rusfertide?
Injection-site reactions in 47% of people in the main trial, and anemia in 26%.
Is rusfertide approved?
Yes, in the US as Mimrylo since August 2026. It is a weekly self-injection given alongside usual treatment.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem